

### **Editor's Comment:**

I have reviewed the manuscript and find it unacceptable for publication in the current format. The authors do not appear to have adequately addressed all of the peer-reviewers comments. There are a number of errors that need to be corrected prior to acceptance. Here is a just a brief recitation of a few of the problems with this paper.

1. Section 2.0 Methods page 3: The sub-bullets are numbered incorrectly. The numbers 2.1 and 2.2 repeat. It is also important to note that no active controls were used in any of the tests outlined in the Methods section nor was there any information on how many times the assays were performed. This was a point raised during the peer review and does not seem to be addressed.
2. Sub-Section 2.1 page 3: The 2nd sentence should start with "It" rather than "I". Who is "Scientist" referred to in this section? There needs to be some detail on how the material was identified and authenticated.
3. Sub-Section 2.1 page 4: This section needs to be re-defined. Caco-2 assessments are not a direct measurement of bioavailability. It is simply a tool used to predict bioavailability. The authors can state this is "Predicted Bioavailability". In the 2nd sentence, it is stated that the cytotoxicity assessments were carried out at 370 C for two hours. I think the authors meant to say 37 C.
4. Sub-Section 2.2, page 5: It is unclear what the authors mean with concentration of 1 µg/mL at the end of the paragraph. There needs to be more detail provided regarding the assay procedures. It doesn't have to be detailed but the highlights need to be included.
5. Sub-Section 2.4, page 5: Please provide the location for Sr. Lifesciences. Please remove the last sentence "What is your positive control?"
6. Sub-Section 2.6, page 6: Please provide a more complete description of the cancer cells used and where they were sourced.

Unless the authors are willing to address all of the issues raised in this critique as well as the peer reviewer's comments, the paper is rejected.

### **Editor's Details:**

Dr. David E. Martin  
Chief Executive Officer, TrippBio, Inc. USA.